Phase 4 Haemophilia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with haemophilia A.
- You are able to read, understand, and sign a consent form agreeing to take part in the study.
- You have been prescribed a specific haemophilia medicine called efanesoctocog alfa as a regular preventive treatment, either within the 6 months before joining the study or at the time of joining.
- You have been on some form of regular preventive haemophilia treatment for at least 12 months before being switched to efanesoctocog alfa.
- There are written records available showing your haemophilia treatments and any bleeding episodes during the 12 months before you were switched to efanesoctocog alfa and up until you join the study.
- You are willing to attend scheduled study visits and complete required health assessments, including joint health checks and questionnaires.
- You (or your legal guardian) are willing and able to keep a record of any bleeding episodes and any treatments used for those bleeds.
- If you are in a specific part of the study called HEAD-US: you agree to have yearly ultrasound scans on certain joints (ankles, elbows, and knees).
Who may not be able to join:
- You have a form of haemophilia A that was not inherited (acquired haemophilia A), or you have a different type of blood clotting disorder.
- Your medical records show that your body has developed antibodies (called inhibitors) that block the haemophilia treatment, at any point between starting efanesoctocog alfa and joining the study.
- You are currently taking part in another clinical trial, or you have taken an experimental medicine (including for haemophilia) within the 3 months before joining this study.
- The study doctor decides, for any reason, that taking part would not be appropriate for you.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Study Physician, Swedish Orphan Biovitrum AB (publ)
Phone: +46 08-697-20 00
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Annualized joint bleeding rate (AjBR) over the prospective observation period.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.